The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 91 (high attention) · dilution pressure elevated · listing risk high · governance risk high · runway n/a · strongest signal: Restatement (non-reliance) (Aug 6, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going concern in 8-k) coexists with live selling machinery (equity line). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
The reported numbers themselves are in question — restatement, late filings or auditor churn. Treat the balance sheet with extra caution. A change of auditor or non-reliance on prior financials, together with late filings or a cluster of executive departures, is the pattern that precedes restatements, deregistration, or fraud allegations.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Late filing (NT) | NT 10-Q filed 2026-08-14 filing | 49 |
| Aug 11, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-11 filing | 51 |
| Aug 11, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K/A (EX-99.2) filed 2026-08-11 filing | 31 |
| Aug 11, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-11 (accepted 19:58 ET) filing | 29 |
| Aug 7, 2026 | ▼ Auditor change | 8-K Item 4.01 filed 2026-08-07 (accepted 17:08 ET) filing | 56 |
| Aug 6, 2026 | ▼ Restatement (non-reliance) | 8-K Item 4.02 filed 2026-08-06 (accepted 17:03 ET) filing | 69 |
| Aug 6, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-06 (accepted 08:30 ET) filing | 61 |
| Aug 6, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-06 filing | 46 |
| Jul 31, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-07-31 filing | 25 |
| Jul 29, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-29 (accepted 08:30 ET) filing | 22 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · OTLK Outlook Therapeutics, Inc. · screener →